Building Biotech Bridges: Accelagen Joins Record attendance at AusBiotech International Conference

Accelagen joined a record gathering of industry leaders in Melbourne for the AusBiotech International Conference 2025,where collaboration, innovation, and optimism defined Australia’s growing rolein global clinical trial development.

This year’s AusBiotech InternationalConference in Melbourne brought together a record breaking gathering of life science professionals. For Accelagen, it was a chance to reconnect with industry peers, strengthen global partnerships, and showcase how Australian innovation continues to stand out in the clinical research industry.

Showcasing Accelagen’s Cross-Functional Clinical Expertise

Accelagen CEO Greg Plunkett and CGO Mat Palmer described the atmosphere as positive and forward looking. “These conferences have grown in size and value for both local and international folk,” Greg said.“It reaffirmed all the work that’s gone on across the industry to heighten awareness of Australia as a chance to celebrate the successes that have emerged here.”

A holistic view of development, combining clinical insight, regulatory expertise, and investor awareness, reflects the company’s broader mission to connect science with success. Accelagen brought a diverse cross-section of its team to Melbourne, giving attendees the opportunity to meet the specialists who drive its clinical programs. “It’s the team that makes Accelagen,” Mat said. “People want to meet the medical monitors, the biometrics team, our start-up specialists and the project leads.The conference gave them that chance.”

Connecting With Partners, Sponsors, and Innovators at AusBiotech

Much of the discussion centred on howAustralia’s biotech ecosystem can strengthen collaboration across its many moving parts. Accelagen noted that AusBiotech had successfully brought together government and industry to explore new ways to support sector growth, from advanced manufacturing and preclinical capability to international market positioning. “It’s about recognising what the capabilities are in Australia and how we can collaborate to enhance value,” Mat said. “We’re already doing a lot of that well, but there’s still room to develop those synergies.”

For Accelagen, the conference enabled connection with partners and collaborators, and to listen to what the sector needs most. The company’s booth attracted steady traffic throughout the event, generating both new relationships and valuable conversations. “People were coming to us with challenges around manufacturing and the preclinical pathway or study design,” Mat explained. “Often we could introduce them to others in the room who could help. It’s that sense of community that makes the Australian biotech scene unique.”

Why Strong Development Strategy Still Attracts Investors

“You can’t take too many steps before you bump into someone you know,” Greg agreed. “It’s an opportunity to reignite collaborations, share ideas, and recognise that helping others ultimately helps the whole ecosystem. That collegial spirit is something Australia does particularly well.”

Despite the successes, there was an undercurrent of tension from a sector facing significant funding pressures.“Everyone’s feeling it,” Greg said. “It’s part of a global trend, and we’re not insulated from it.”

“With challenge comes opportunity,” Mat said.“If you can demonstrate a clear development picture and a good story, investors will still support you. They’ll just do it with more scrutiny. That’s why getting the fundamentals right matters more than ever.”

Australia’s Global Reputation for Clinical Trial Excellence

Australia’s dependable drug development framework, access to world class science, and stable governance continue to attract international sponsors. As Mat noted, “A significant proponent of new drug applications globally include Australian data. That tells you something about how highly our work is regarded.” As regulatory startup times and national coordination continue to improve, Australia’s position as a preferred destination for clinical trials is becoming more entrenched.

Discussions throughout the event also acknowledged the pressure on patient recruitment as demand for Australian trial capacity increases. Greg explained that in some therapeutic areas, “there is such a demand for running programs that you have to be more strategic in recruiting the patient population and casting the net wider to identify the right sites to support the studies.” Accelagen’s response has been to expand its network beyond traditional centres and design trials with the patient experience in mind.

Patient-Centric Trial Design as a Competitive Advantage

The company also emphasises patient-centrictrial design as a competitive advantage. Reducing barriers to participation, aligning study design with patient needs, and ensuring clinical sites are well supported all contribute to faster, more effective recruitment. “If you can design a program that achieves its objectives and supports patients along the way, it becomes far more attractive for participation,” Greg said.

From a strategic standpoint, Accelagen ensures that every new study is properly assessed for feasibility before launch. “We don’t take on programs that can’t be executed,” Mat said. “We build strong relationships with key opinion leaders and study sites, and we make sure we understand the patient journey. That allows us to give better input into study design and to add value from phase one through our partnership discussions.”

Strengthening Accelagen’s Role in Australia’s Biotech Ecosystem

As the sector continues to evolve, Accelagen’s presence at the AusBiotech International Conference reaffirmed its position within Australia’s growing biotech ecosystem. It solidified our offering,” Greg said. “We found new opportunities to support both local and international development.”

Mat agreed. “People were genuinely looking for help, and our team was able to provide it,” he said. “It showed that what we do adds value not only for our clients but for the broader sector as well.”

The AusBiotech International Conference 2025demonstrated that the foundations of Australia’s biotech strength remain as strong as ever. For Accelagen, the event confirmed that the nation’scombination of scientific depth and cooperative culture continues to offer a compelling environment for global clinical development.

‍